NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Coave Therapeutics

Coave Therapeutics

Private
ParisHealthcare & Life Scienceshttps://coavetx.com/

Last Round

Series A

Jan 9, 2025

Total Funding Raised

$131.4M

Company Overview

Coave Therapeutics is a biotechnology company that develops targeted gene therapies for rare ocular and central nervous system (CNS) diseases using its proprietary ALIGATER™ platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyALIGATERAAVbiotechadeno-associated virustargeted deliveryvector engineeringgenetic medicinerare diseaseprecision medicineocular gene therapyneurological gene therapybiopharmadrug discoveryclinical-stage biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Coave Therapeutics Comparables

Compare Coave Therapeutics with similar companies based on industry and business-model similarity.

Coave Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Capsida Biotherapeutics
84%
AviadoBio
79%
Atsena Therapeutics
78%

Coave Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJan 9, 2025
Series AJan 9, 2025
Series BJul 21, 2021
Series BNov 8, 2017
Series AJul 8, 2016

Coave Therapeutics Investors

Notable investors and investment history

Coave Therapeutics investors
InvestorRounds
Fund+Series B, Series A
Seroba Life SciencesSeries A, Series B
Pontifax Venture CapitalSeries B
BpifranceSeries A
Turenne GroupeSeries B, Series A
Eurazeo Investment ManagerSeries B
V-Bio VenturesSeries B

Coave Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Coave Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Coave Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersParis
Employee Range46
Year Founded2014
Last FundingJan 9, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.